NCT06287073Completed
JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
A Regulatory Non-interventional Study to Monitor the Safety and Efficacy of JARDIANCE® (Empagliflozin 10 mg) in Korean Patients With Chronic Kidney Disease (CKD)
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice. The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 299 (actual)
- First submitted
- 23 Feb 2024
- Start date
- 29 Mar 2024
- Primary completion date
- 30 Apr 2025
- Lead sponsor
- Boehringer Ingelheim
- Diseases
- Chronic kidney disease
- NCT number
- NCT06287073
What you commit to
- Study type: Observational
- Participants enrolled: 299
- From 29 Mar 2024 to the primary completion date, 30 Apr 2025
- 12 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with previous exposure to JARDIANCE®
Other illness
- Patients with hypersensitivity to empagliflozin or to any of the excipients
- Patients with type 1 diabetes
- Patients with history of Diabetic Ketoacidosis (DKA)
Lab values
- Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
Other
- Patients who are pregnant or are breastfeeding or who plan to become pregnant during the study period
Who the study is looking for
- Age ≧19 years at enrolment
- Patients diagnosed with CKD
- Patients with CKD starting JARDIANCE® for the first time in accordance with the approved label in Korea
- Patients who have provided informed consent and signed the data release consent form
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (12)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hallym University Sacred Heart Hospital Coordinator of this site? Confirm its status | Anyang | South Korea | Unknown status |
| Chungbuk National University Hospital Coordinator of this site? Confirm its status | Cheongiu | South Korea | Unknown status |
| Yonsei University Wonju Severance Christian Hospital Coordinator of this site? Confirm its status | Gangwon | South Korea | Unknown status |
| Inje University Ilsan Paik Hospital Coordinator of this site? Confirm its status | Goyang | South Korea | Unknown status |
| Chonnam National University Hospital Coordinator of this site? Confirm its status | Gwangju | South Korea | Unknown status |
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| SoonChunHyang University Hospital Seoul Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| The Catholic University of Korea, Eunpyeong St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| The Catholic University of Korea Yeouido St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Korea University Anam Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
| Ulsan University Hospital Coordinator of this site? Confirm its status | Ulsan | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.